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&p.1:Abstract. Fluorine-18 fluorodeoxyglucose positron
emission tomography (FDG PET) has proven useful in
the differentiation of various tumour entities, including
breast cancer. In patients with primary breast cancer we
performed a 3-h imaging protocol to examine possible
improvements in tumour detectability and image con-
trast. Twenty-nine patients with primary breast cancer
with a diameter of ‡ 2 cm that was demonstrated to be
malignant by biopsy or surgery were injected with
370–740 MBq 18F-FDG and scanned in the prone posi-
tion. Data were acquired 0–40 min, 1.5 h and 3.0 h after
injection. After correction for measured attenuation, de-
cay and scatter and iterative reconstruction, standardised
uptake values (SUVs) and tumour-to-non-tumour and tu-
mour-to-organ ratios were calculated. Visual analysis
was performed using transverse, sagittal and coronal
slices as well as 3D reprojection images. Tumour-to-
non-tumour and tumour-to-organ ratios were significant-
ly higher for the 3-h images than for the 1.5-h images.
SUVs did not increase to the same extent. Lesion detect-
ability was 83% in 1.5-h images compared to 93% in 3-h
images. We conclude that tumour contrast in breast can-
cer is improved by starting the PET acquisition at 3 h
p.i. rather than at 1.5 h p.i.
&kwd:Key words: Breast cancer – Fluorine-18 fluorodeoxyglu-
cose – Positron emission tomography – Tumour-to-non-
tumour ratio – Contrast parameters
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Introduction
Fluorine-18 fluorodeoxyglucose positron emission to-
mography (FDG PET) has proven useful in the primary
detection and follow-up of many tumours including
breast cancer [1–6], in which there is an over-expression
of Glut1 glucose transporters [7]. Nevertheless, the sig-
nificance of FDG PET for clinical management and out-
come in breast cancer is still uncertain [8]. On the other
hand, FDG PET seems beneficial in the diagnosis of re-
current, metastatic [9, 10] or multifocal disease, in thera-
py monitoring [11, 12] and even in directing surgery
[13]. For the re-staging of breast cancer patients, FDG
PET appears to be the most accurate method available
[14].
One reason for these dicrepancies and for the non-op-
timal specificity of FDG PET [15] may be the use of dif-
ferent technical and methodological approaches. With
regard to variation in normal tissue FDG uptake [16], the
use of standardised uptake values (SUVs) [3, 17, 18]
should be useful in the assessment of PET data and the
evaluation of glucose hypermetabolism; however, a criti-
cal issue in this respect is the time interval between FDG
injection and measurement. SUVs obtained from data
acquired 30–60 min after FDG administration have been
applied in the differentiation of breast malignancies
[19–21], but since inflammatory lesions accumulate
FDG more early and more intensely than malignancies
[22], the detectability of malignant foci may be im-
paired. Therefore, we prospectively and pre-operatively
evaluated a 3-h acquisition protocol in 29 patients with
breast cancer. FDG PET findings recorded at 1.5 and 3 h
post injection (p.i) were compared with regard to SUVs,
target-to-non-target and target-to-background ratios and
qualitative blind reading by physicians.
Materials and methods
Patients. &p.2:Twenty-nine female patients were investigated, three of
them repeatedly, because of focal breast lesions highly suggestive
of breast cancer magnetice resonance imaging (MRI) and mam-
mography. The patients’ ages ranged from 34 to 63 years. All tu-
mours were histologically proven using jet biopsies or surgery.
Patient and tumour characteristics are shown in Table 1. Diabetic
patients were excluded. All patients were fasted for at least 12 h
and had blood glucose levels below 100 mg%. To be eligible for
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the protocol, patients had to be able and willing to lie on a PET
bed in the prone position for a total of more than 3 h. Informed
consent was obtained beforehand.
Methods. &p.2:In all patients, transmission scans ( ‡ 900 s or ‡ 106
counts per bed position) in the prone position were performed pri-
or to injection of 370–740 MBq of 18F-FDG. A CTI ECAT EX-
ACT HR + [full-width at half-maximum (FWHM) 4.5 mm, 15 cm
transaxial field of view (FOV)] and a GE/SCX PC 4096 WB+
(FWHM 5.1 mm, 10 cm transaxial FOV) PET scanner were em-
ployed. Immediately after injection the first scan was started with
the subsequent scans starting at 1.5 and 3 h.
After correction for random and scattered coincidences, dead
time and decay, data were reconstructed with an iterative algo-
rithm. Documentation carried out as 3D maximum re-projection
in six whole-body views (anterior, posterior, right and left lateral,
Table 1. Patient and tumour characteristics &/tbl.c:&tbl.b:
Patient age (years) No. Tumour diameter Oestrogen receptor Tumour staging
(median±SEM*) (cm) (median±SEM*) positive (No.) (lowest – highest stage)
Ductal invasive 45±8 18 2.9±0.6 5/18 pT2N0M0G2 – pT4N1M0G3
Lobular invasive 47±2 7 3.5±1.0 3/7 pT2N0M0G2 – pT4N1bM1G2
Inflammatory 40±2 2 6.3±2.2 0/2 pT2N1aM0G3 – pT4N2M1G3
Other 46±4 2 4.2±0.2 0/2 pT3N1M0 – pT4aN1M1
&/tbl.b:
Fig. 1A–D. Two examples of the
visualisation of large breast can-
cers (3.5 and 7.6 cm in maximum
diameter) 1.5 and 3 h p.i. A Lobu-
lar invasive  breast cancer; images
obtained 90 min after injection of
550 MBq 18F-FDG. B Same pa-
tient as in A, images obtained
180 min after injection. C Ductal
invasive breast cancer; images ob-
tained 90 min after injection of
560 MBq 18F-FDG. D Same pa-
tient as in C; images obtained
180 min after injection &/fig.c:
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right and left anterior oblique) and in coronal, sagittal and trans-
verse slices. The quantitative evaluation was based on a region of
interest (ROI) analysis and yielded SUVs for the tumour as well
as tumour-to-non-tumour (= contralateral breast), tumour-to-back-
ground (= mediastinum) and tumour-to-organ (= myocardium, liv-
er and bone marrow) ratios. SUVs were calculated as decay-cor-
rected ROI maximum/tumour (kBq/g) divided by injected activi-
ty/body weight (MBq/kg).
The number of pathological lesions was determined indepen-
dently by three experienced physicians without knowledge of the
patients’ histories.
Statistics. &p.2:Kolmogorov-Smirnov tests failed to show a normal dis-
tribution for any of the parameters tested. Statistical analysis was
carried out by computing the median and standard error of the me-
dian [SEM* = (max.–min. value): 3.4641] unless stated otherwise,
and by performing non-parametric tests (Wilcoxon test, Mann-
Whitney U test, or Kruskal-Wallis test).
Results
Patients with ductal invasive, lobular invasive and other
breast cancers showed no significant differences with re-
gard to age, tumour stage or percentage of oestrogen re-
ceptor-positive tumours. The two patients with inflam-
matory cancers were slightly younger and had larger tu-
mours at presentation. Typical examples of the visualisa-
tion of tumours 1.5 and 3 h p.i. are shown in Fig. 1.
Fig. 2 illustrates the tumour-to-non-tumour ratios over
time for the three predominant tumour types. Tumours
were more clearly delineated on the later scans. Of 29
histologically proven primary breast cancers, 24 were di-
agnosed on the scans done at 1.5 h p.i. Examining the
scans acquired 3 h after injection, 27 of the 29 tumours
were adjudged pathological. Two breast tumours, both
invasive ductal cancers, were visualised neither on the
early nor on the late scans. In 4 of 29 patients a complete
and accurate diagnosis was possible only by reference to
the late images. Thirteen multifocal tumours appeared
diffuse on the early scans but were clearly depicted on
the 3-h scans. Lymph node involvement was present in
18 patients and was correctly diagnosed on all 3-h scans,
whereas it was not visible in six patients on the 1.5-h
scans. Visual analysis indicated no advantages of early
over late imaging as no primary tumour or metastasis
was diagnosed only by reference to early scans.
Due to a large variance, SUVs (Table 2) did not differ
significantly at the two scan times, being 6.6±5.0 at
1.5 h versus 11.8±6.6 at 3 h after injection (representing
an enhancement of approximately 80%). In contrast, tu-
mour-to-background and tumour-to-non-tumour ratios as
well as tumour-to-liver, tumour-to-bone marrow, tu-
mour-to-mediastinum and tumour-to-myocardium ratios
rose significantly (Table 3).
Discussion
Previous studies were able to demonstrate that about
10% of breast cancers do not accumulate FDG [23]. Our
findings were similar, in that 2/29 patients were not cor-
rectly diagnosed by reference to the 3- and 1.5-hour
scans. Comparing the scan times employed in our study,
the results provide evidence that tumour contrast and de-
Fig. 2. Changes in tumour-to-non-tumour ratios (median ±SEM*)
over time in the three predominant tumour types: lobular invasive,
ductal invasive and inflammatory breast cancer &/fig.c:
Table 2. SUVs at 1.5 and 3 h p.i. (n = 27 tumours) &/tbl.c:&tbl.b:
1.5 h p.i. 3 h p.i. Increase
(median±SEM*) (median±SEM*) (%)
6.6±5.0 11.8±6.6 79
&/tbl.b:
Table 3. Results in respect of contrast parameters at 1.5 and 3 h p.i. (n = 27 tumours) &/tbl.c:&tbl.b:
1.5 h p.i. 3 h p.i Increase at 3.0 h Significance
(median±SEM*) (median±SEM*) versus 1.5 h (%) (Wilcoxon test)
Tumour/breast 3.4±1.3 14.7±6.8 332 0.003
(tumour/non-tumour)
Tumour/mediastinum 1.2±0.6 6.1±3.0 408 0.001
(Tumour/background)
Tumour/myocardium 0.8±0.5 3.2±1.2 300 0.003
Tumour/bone marrow 1.1±0.9 4.0±2.2 263 0.01
Tumour/liver 1.0±0.7 3.4±2.0 240 0.008
&/tbl.b:
tectability are better at 3 h p.i. If glucose hypermetabo-
lism is present, the low levels of glucose-6-phosphatase
expressed by breast tissue and tumours derived there-
from prevent early washout of the radioactive label.
Comparisons of glucose metabolism in breast and lung
cancer revealed significantly higher glucose transport
and utilisation but also an early washout of radioactive
label in lung cancer [20, 24], resulting in superiority of
1-h FDG scans.
The goal in FDG-PET in patients with breast cancer
must be to enhance diagnostic accuracy. This is to be
achieved by avoiding non-diagnostic scans with consid-
erable FDG accumulation in normal glandular breast tis-
sue, equivocal target-to-background ratios and poor im-
age quality (all of which obscure small tumour foci).
The data presented demonstrate that sensitivity is in-
creased by scanning at 3 h rather than 1.5 h p.i.
No purely inflammatory or other benign lesions were
observed in our study as MRI proved highly accurate.
Still, judging from other tumours like pancreatic [25] or
head/neck masses [26] the problem of differentiating in-
flammatory disease from malignancy will not be solved
by changes in imaging procedures. Inflammatory cells
accumulate FDG early and intensively, with SUVs in the
same range as many malignant tumours. Washout phe-
nomena are not reported earlier or more often in inflam-
mation [22]. However, as tumour-to-bone marrow ratios
are significantly higher at 3 h than at 1.5 h p.i. (Table 2)
(probably as a consequence of measurable efflux of ra-
dioactivity from white blood cells and their precursors),
there is hope that better differentiation of tumour and in-
flammation will be possible using late scans.
The metabolite basis for interpreting FDG imaging
data is far less developed [27] compared to visual analy-
sis. Scan protocols have varied with regard to the timing
of data acquisition, depending on the tumour under inves-
tigation. According to Fischman and Alpert [28], most of
the radiation emitted from tissue within the first hour af-
ter injection comes from intracellular FDG-6-PO4, and in
the absence of significant glucose-6-phosphatase activity
the concentration of FDG in tissue will eventually reach a
plateau representing the metabolically trapped 18F label.
As yet, there is no evidence that breast malignancies
achieve FDG plateau concentrations within 60 min after
injection [29]. The results presented to date clearly show
that the FDG kinetics of every tumour type studied clini-
cally must be better understood in order for more mean-
ingful results to be obtained [28]. Recently, findings of a
correlation between prognostic indices like histopatho-
logical grading or p53 expression and FDG uptake have
been reported [30]. As tumour-to-breast tissue ratios tend
to change rapidly over the first hour post injection, a
suitable later scan time seems more for longitudinal stud-
ies using FDG PET. Use of later scanning should reduce
biological and inter-observer variability and improve
evaluation of tumour glycolytic rates [31]. Furthermore,
patients may be spared time-consuming procedures in the
prone position, which is essential for differentiation of
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breast tissue and the underlying chest wall as well as for
any overlay technique with MRI data.
&p.2:We would like to thank the staff of the PET laboratory, Institute of
Medicine, Research Centre Jülich, and especially Mrs. Liesel The-
elen and Mr. Lutz Tellmann, for expert technical assistance and
help in data acquisition, data management and documentation.
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